CN Patent

CN109988112A — 仑伐替尼甲磺酸盐的晶型及其制备方法

Assigned to Sichuan Kelun Pharmaceutical Research Co Ltd · Expires 2019-07-09 · 7y expired

What this patent protects

本发明公开了一种仑伐替尼甲磺酸盐的晶型、制备方法、包含晶型的药物组合物以及所述的晶型在制备用于治疗侵袭性、分化型甲状腺癌的药物中的用途。所述的仑伐替尼甲磺酸盐的晶型，其X射线粉末衍射图包括在约16.1±0.2°，17.8±0.2°，18.8±0.2°,25.0±0.2°，25.4±0.2°的衍射角(2θ)处的峰。

USPTO Abstract

本发明公开了一种仑伐替尼甲磺酸盐的晶型、制备方法、包含晶型的药物组合物以及所述的晶型在制备用于治疗侵袭性、分化型甲状腺癌的药物中的用途。所述的仑伐替尼甲磺酸盐的晶型，其X射线粉末衍射图包括在约16.1±0.2°，17.8±0.2°，18.8±0.2°,25.0±0.2°，25.4±0.2°的衍射角(2θ)处的峰。

Drugs covered by this patent

Patent Metadata

Patent number
CN109988112A
Jurisdiction
CN
Classification
—
Expires
2019-07-09
Drug substance claim
No
Drug product claim
No
Assignee
Sichuan Kelun Pharmaceutical Research Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.